FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 334:1599-1600 June 13, 1996 Number 24 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Fifteen years ago, after the National Cooperative Crohn's Disease Study (NCCDS)¹ had found that patients in remission who were given placebo fared better than those given corticosteroids, azathioprine, or a 5-aminosalicylate–sulfonamide compound, the approach to preventing relapse in patients with Crohn's disease was nihilistic. Now, the view among physicians is very different. New 5-aminosalicylates delivering larger amounts of the drug to the bowel can delay relapse,² as can low-dose corticosteroids,³ and new, poorly absorbed corticosteroids, which have minimal side effects, are becoming available. Immunosuppressant drugs, at least in combination with a corticosteroid, have been proved to prolong corticosteroid-induced remissions.⁴

These . . . [Full Text of this Article]

References

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.